Hyperthermic intraperitoneal perfusion chemotherapy—views on the observed variability in oxaliplatin pharmacokinetics
- 15 November 2008
- journal article
- letter
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 65 (3) , 321-322
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Significance of Organic Cation Transporter 3 (SLC22A3) Expression for the Cytotoxic Effect of Oxaliplatin in Colorectal CancerDrug Metabolism and Disposition, 2008
- Systemic exposure of the parent drug oxaliplatin during hyperthermic intraperitoneal perfusionEuropean Journal of Clinical Pharmacology, 2008
- Swedish Experience with Peritonectomy and HIPEC. HIPEC in Peritoneal CarcinomatosisAnnals of Surgical Oncology, 2007
- Population pharmacokinetics of gemcitabine and its metabolite in patients with cancer: effect of oxaliplatin and infusion rateBritish Journal of Clinical Pharmacology, 2007
- Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicityBiochemical Pharmacology, 2007
- Cisplatin and Oxaliplatin, but Not Carboplatin and Nedaplatin, Are Substrates for Human Organic Cation Transporters (SLC22A1–3 and Multidrug and Toxin Extrusion Family)The Journal of Pharmacology and Experimental Therapeutics, 2006
- Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracilAnnals of Oncology, 2005
- Continuous Infusion of Oxaliplatin plus Chronomodulated Capecitabine in 5-Fluorouracil- and Irinotecan-Resistant Advanced Colorectal Cancer PatientsOncology, 2005
- Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapyCancer, 2001
- Influence of infusion time on unchanged cisplatin disposition in patients with ovarian cancerCancer Chemotherapy and Pharmacology, 1989